The regulatory saga of fedratinib

Robie-Suh K. Center for drug evaluation and research multi-discipline review, Application Number: 212327Orig1s000, www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212327Orig1s000MultidisciplineR.pdf (2019, accessed 6 February 2020).

Verstovsek S Mesa RA Gotlib J , et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799–807.

Taylor NP Idrus AA Adams B. Second phase III study of novartis JAK inhibitor INC424 meets primary endpoint in patients with myelofibrosis. FierceBiotech, www.fiercebiotech.com/biotech/second-phase-iii-study-of-novartis-jak-inhibitor-inc424-meets-primary-endpoint-patients. (2011, accessed 26 April 2021).

Incyte announces positive top-line results from COMFORT-I Pivotal Phase III Trial of INCB18424 in Myelofibrosis, a Debilitating, Life-Threatening Blood Cancer. Incyte Corporation, https://investor.incyte.com/press-releases/press-releases/2010/Incyte-Announces-Positive-Top-Line-Results-from-COMFORT-I-Pivotal--Phase-III-Trial-of-INCB18424-in-Myelofibrosis-a-Debilitating--Life-Threatening-Blood-Cancer/default.aspx (2010, accessed 11 May 2021).

Pardanani A Harrison C Cortes JE , et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis. JAMA Oncol 2015; 1: 643.

Hilal T Sonbol MB Prasad V. Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US food and drug administration. JAMA Oncol 2019; 5: 887–892.

Harrison CN Schaap N Vannucchi AM , et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol 2017; 4: e317–e324.

Harrison CN Schaap N Vannucchi AM , et al. Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): a reanalysis of the JAKARTA2 study. JCO 2019; 37: 7057–7057.

Harrison CN Mesa RA Jamieson C , et al. Case series of potential Wernicke’s encephalopathy in patients treated with fedratinib. Blood 2017; 130: 4197.